Table 1.
Comparisons of Demographic Characteristics and Comorbidities in Patients with and without IBD
| Characteristics | IBD | CD | UC | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| Non-IBD cohort (n=150,500) | IBD cohort (n=30,100) | p-value | Non-CD cohort (n=52,585) | CD cohort (n=10,517) | p-value | Non-UC cohort (n=97,915) | UC cohort (n=19,583) | p-value | |
| Age, yr | 37.4±15.8 | 37.4±15.8 | - | 29.0±13.3 | 29.0±13.3 | - | 41.9±15.3 | 41.9±15.3 | - |
| <15 | 5,545 (3.7) | 1109 (3.7) | 3,925 (7.5) | 785 (7.5) | 1,620 (1.7) | 324 (1.7) | |||
| 15–29 | 49,100 (32.6) | 9,820 (32.6) | 27,925 (53.1) | 5,585 (53.1) | 21,175 (21.6) | 4,235 (21.6) | |||
| 30–44 | 47,790 (31.8) | 9,558 (31.8) | 14,180 (27.0) | 2,836 (27.0) | 33,610 (34.3) | 6,722 (34.3) | |||
| 45–59 | 32,995 (21.9) | 6,599 (21.9) | 4,680 (8.9) | 936 (8.9) | 28,315 (28.9) | 5,663 (28.9) | |||
| ≥60 | 15,070 (10.0) | 3,014 (10.0) | 1,875 (3.6) | 375 (3.6) | 13,195 (13.5) | 2,639 (13.5) | |||
| Male sex | 95,700 (63.6) | 19,140 (63.6) | - | 37,960 (72.2) | 7,592 (72.2) | - | 11,548 (59.0) | - | - |
| Rural area | 80,320 (53.4) | 14,940 (49.6) | <0.001 | 27,990 (53.2) | 5,143 (48.9) | <0.001 | 52,330 (53.4) | 9,797 (50.0) | <0.001 |
| Lowest income quintile | 34,647 (23.0) | 5,964 (19.8) | <0.001 | 12,121 (23.1) | 2,220 (21.1) | <0.001 | 22,526 (23.0) | 3,744 (19.1) | <0.001 |
| Underlying diseases | |||||||||
| Diabetes mellitus | 5963 (4.0) | 1,006 (3.3) | <0.001 | 954 (1.8) | 176 (1.7) | 0.321 | 5,009 (5.1) | 830 (4.2) | <0.001 |
| Hypertension | 15,432 (10.3) | 2,846 (9.5) | < 0.001 | 2,360 (4.5) | 429 (4.1) | 0.063 | 13,072 (13.4) | 2,417 (12.3) | 0.001 |
| Dyslipidemia | 8,876 (5.9) | 1,732 (5.8) | 0.334 | 1,451 (2.8) | 260 (2.5) | 0.098 | 7,425 (7.6) | 1,472 (7.5) | 0.749 |
| Cancer | 1,928 (1.3) | 531 (1.8) | <0.001 | 296 (0.6) | 108 (1.0) | <0.001 | 1,632 (1.7) | 423 (2.2) | <0.001 |
| IBD medications | |||||||||
| Steroid | 45,723 (30.4) | 17,104 (56.8) | <0.001 | 14,452 (27.5) | 6,140 (58.4) | <0.001 | 31,271 (32.0) | 10,964 (56.0) | <0.001 |
| Immunosuppressant | 394 (0.3) | 8,605 (28.6) | <0.001 | 97 (0.2) | 6,012 (57.2) | <0.001 | 297 (0.3) | 2,593 (13.2) | <0.001 |
| Anti-TNF agent | 24 (0.0) | 1,737 (5.8) | <0.001 | 11 (0.0) | 1,405 (13.4) | <0.001 | 13 (0.0) | 332 (1.7) | <0.001 |
| Follow-up period, yr | 4.8±1.3 | 4.7±1.4 | <0.001 | 4.9±1.3 | 4.7±1.4 | <0.001 | 4.8±1.4 | 4.8±1.4 | <0.001 |
Data are presented as mean±SD or number (%).
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; TNF, tumor necrosis factor.